Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group

BACKGROUND: Our objective was to determine whether anti-interleukin (IL)-6 receptors improve outcomes of critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia. We report on two cohort-embedded, investigator-initiated, multicentre, open-label, Bayesian randomised controlled clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermine, Olivier, Mariette, Xavier, Porcher, Raphael, Resche-Rigon, Matthieu, Tharaux, Pierre-Louis, Ravaud, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819469/
https://www.ncbi.nlm.nih.gov/pubmed/35115337
http://dx.doi.org/10.1183/13993003.02523-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819469/
https://www.ncbi.nlm.nih.gov/pubmed/35115337
http://dx.doi.org/10.1183/13993003.02523-2021

Ejemplares similares